On 18 January 2022, the Canadian Agency for Drugs and Technologies in Health (CADTH) and the Pan-Canadian Formulary Advisory Panel held an information session about a potential pan-Canadian formulary (for further details, see "Pan-Canadian Formulary Advisory Panel holds information session on proposed framework for potential pan-Canadian formulary").

On 11 January 2022, the CADTH posted a discussion paper about the proposed framework for a potential pan-Canadian formulary, which included a discussion of the proposed principles, values and criteria to guide the development as well as a proposed sample list of drugs focusing on commonly prescribed drugs and related products in three therapeutic areas (cardiovascular disease, diabetes and psychiatric illness).

The CADTH also provided an online questionnaire for stakeholders to provide feedback. The online consultation period ran until 25 February 2022.

For further information on this topic please contact Urszula Wojtyra at Smart & Biggar by telephone (+1 416 593 5514) or email ([email protected]). The Smart & Biggar website can be accessed at www.smartbiggar.ca.